Rituximab, a chimeric anti-CD20 monoclonal antibody, is widely used in the treatment of non-Hodgkin lymphoma (NHL) and other B-cell malignancies. The traditional IV formulation, while effective, requires prolonged infusion times and significant resources. To address these challenges, a SC formulation of rituximab has been developed, offering a quicker administration time of 5 to 7 minutes with 15 minutes of monitoring post-administration.
A retrospective, observational analysis was conducted at Memorial Sloan Kettering Cancer Center (MSKCC) to evaluate the real-world impact of SC rituximab on patient care and practice efficiency. The study focused on changes in chair occupancy time and prescribing patterns before and after the adoption of SC rituximab. Data from September 2016 through September 2018 were analyzed, with SC rituximab added to the hospital formulary in September 2017.
The study found that SC rituximab significantly reduced chair time for patients, with a 37% reduction in combination therapy and a 62% reduction in monotherapy compared to IV administration. This reduction in chair time translates to substantial time savings for both patients and healthcare providers, potentially allowing for more patients to be treated within the same timeframe. Additionally, the study observed heterogeneous prescribing patterns among doctors, influenced by patient diagnosis and age, highlighting the need for further education on the benefits of SC rituximab.
The findings suggest that the adoption of SC rituximab can lead to improved practice efficiency and patient care access, particularly in high-volume cancer centers. The study underscores the importance of considering the economic and resource implications of treatment options in oncology, especially in the context of increasing healthcare expenditures and limited resources.
